#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Our Experience with Ustekinumab for the Treatment of Psoriasis


Authors: N. Vojáčková;  J. Fialová;  Z. Kružicová;  J. Hercogová
Authors‘ workplace: Dermatovenerologická klinika 2. LF UK a FN Na Bulovce přednosta prof. MUDr. Jana Hercogová, CSc.
Published in: Čes-slov Derm, 86, 2011, No. 4, p. 198-202
Category: Case Reports

Overview

Three cases of patients with severe chronic plaque psoriasis in whom classical systemic therapy failed or was discontinued due to side effects are described. After three months of ustekinumab administration more than a year-long remission was achieved in all cases. The therapy is tolerated well, followed laboratory tests are within normal range. Authors draw attention to the new biological agent in the treatment of severe plaque psoriasis.

Key words:
biological therapy – ustekinumab – effectiveness – safety


Sources

1. BENÁKOVÁ, N., ŠTORK, J. Léčba psoriázy biologiky. Konsenzuální doporučené postupy České dermatologické společnosti ČLS JEP 2006. Čes.-slov. Derm., 81, 2006, 4, s. 1–11.

2. BENÁKOVÁ, N., ŠTORK, J. Novinky v léčbě psoriázy biologiky a standardními systémovými léky. Čes.-slov. Derm., 2008, 83, 4, s. 191–202.

3. BOEHNCKE, W. H., KATSAMBAS, A., ORTONNE, J. P. et al. EADV preceptorship: advances in dermatology. JEADV, 2010, 24, Suppl. 5, p. 2–24.

4. FIALOVÁ, J., HERCOGOVÁ, J. Psoriáza. Postgraduální medicína, 2010, 12, 4, s. 435–442.

5. GRIFFTHS, A., STROBER, B. E., VAN DE KERKHOF, P. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med., 2010, 362, p. 118–128.

6. GOTTLIEB, A., MENTER, A., MENDELSOHN, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet, 2009, 373, p. 633–640.

7. HERCOGOVÁ, J. Biologická léčba psoriázy. Postgraduální medicína, 2010, 12, 2, s. 132–138.

8. HERCOGOVA, J., RICCERI, F., TRIPO, L., LOTTI, T., PRIGNANO, F. Psoriasis and body mass index. Dermatol. Therapy., 2010, 23, 2, p. 152–154.

9. LEONARDI, C., KIMBALL, A. B., PAPP, K. A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet, 2008, 371, p. 1665–1674.

10. LOTTI, T., DELESCLUSE, J., HERCOGOVA, J. Established treatments for psoriasis. A critical review. Int. J. Immunopathol. Pharmacol. Sec. Dermatol., 2002, 13, Suppl. 1, p. 5–10.

11. LOTTI, T., HERCOGOVA, J., PRIGNANO, F. The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities? Dermatol. Therapy, 2010, 23, 2, p. 119–122.

12. MENTER, A., KORMAN, N., ELMETS, C. A. et al. Guidelines of care for management of psoriasis and psoriatic arthritis. J. Am. Acad. Dermatol., 2011, in press 10.1016/j.jaad.2010.11.055.

13. NĚMCOVÁ, A., FIALOVÁ, J., HERCOGOVÁ, J. Závažný typ psoriázy s výrazným psychickým postižením léčený efalizumabem. Čes.-slov. Derm., 2008, 83, 1, s. 33–36.

14. PAPP, K. A., LANGLEY, R. G., LEBWOHL, M. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet, 2008, 371, p. 1675–1684.

15. PIETRZAK, A., CHODOROWSKA, G., SZEPIETOWSKI, J., ZALEWSKA-JANOWSKA, A., KRASOWSKA, D., HERCOGOVA, J. Psoriasis and serum lipid abnormalities. Review Dermatol. Therapy, 2010, 23, 2, p. 160–173.

16. REICH, K. Cardiovascular safety of ustekinumab in patients with moderate-to-severe psoriasis:Results of integrated analyses of data from phase II and III clinical studies. Br. J. Dermatol., 2011, in press.

Labels
Dermatology & STDs Paediatric dermatology & STDs
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#